LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria

Journal of Clinical Investigation

Volumn 101, Issue 10, 1998, Pages 2065-2071

  Lamping, Norbert ^a   Dettmer, Rudolf ^a   Schröder, Nicolas W J ^a   Pfeil, Dagmar ^a   Hallatschek, Werner ^a   Burger, Reinhard ^b   Schumann, Ralf R ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Antagonist and inhibitors; Gram negative bacterial infection; Lipopolysaccharides; Macrophage activation; Septic shock therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; BACTERIUM LIPOPOLYSACCHARIDE; BINDING PROTEIN; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GALACTOSAMINE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE PHASE RESPONSE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTEREMIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; FEMALE; GRAM NEGATIVE BACTERIUM; HOST SUSCEPTIBILITY; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER FAILURE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; SEPTIC SHOCK;

EID: 0032523815     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI2338     Document Type: Article

References (51)

1. Raetz, C.R., R.J. Ulevitch, S.D. Wright, C.H. Sibley, A. Ding, and C.F. Nathan. 1991. Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB (Fed. Am. Soc. Exp. Biol.) J. 5:2652-2660.
2. Ulevitch, R.J., and P.S. Tobias. 1995. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu. Rev. Immunol. 13:437-457.
3. Pajkrt, D., and S.J.H. van Deventer. 1996. The cellular response in sepsis. Curr. Top. Microbiol. Immunol. 216:119-132.
4. Glauser, M.P., G. Zanetti, J.-D. Baumgartner, and J. Cohen. 1991. Septic shock: pathogenesis. Lancet. 338:732-736.
5. Parillo, J.E. 1993. Pathogenic mechanisms of septic shock. N. Engl. J. Med. 328:1471-1477.
6. Dellinger, R.P., S.M. Opal, D. Rotrosen, A.F. Suffredini, J.L. Zimmerman, R.C. Bone, C.H. Bosken, P. Dellinger, R.A. Goldstein, S. Hurd, et al. 1997. From the bench to the bedside: the future of sepsis research. Chest. 111: 744-753.
7. Morrison, D.C., and J.L. Ryan. 1987. Endotoxin and disease mechanisms. Annu. Rev. Med. 38:417-432.
8. Raetz, C.R.H. 1990. Biochemistry of endotoxins. Annu. Rev. Biochem. 59:129-170.
9. Lynn, W.A., and D.T. Golenbock. 1992. Lipopolysaccharide antagonists. Immunol. Today. 13:271-276.
10. Rietschel, E.T., H. Brade, O. Holst, L. Brade, L.S. Müller, U. Mamat, U. Zähringer, F. Beckmann, U. Seydel, K. Brandenburg, et al. 1996. Bacterial endotoxin: chemical constitution, biological recognition, host response, and immunological detoxification. Curr. Top. Microbiol. Immunol. 216:39-81.
11. Alexander, J.W., S.T. Boyce, and J.K. Roche. 1990. The process of microbial translocation. Ann. Surg. 212:496-510.
12. Tobias, P.S., K. Soldau, and R.J. Ulevitch. 1986. Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum. J. Exp. Med. 164:777-793.
13. Lamping, N., A. Hoess, B. Yu, T.C. Park, C.J. Kirsehning, D. Pfeil, D. Reuter, S.D. Wright, F. Herrmann, and R.R. Schumann. 1996. Effects of site directed mutagenesis of basic residues (Arg 94, Lys 95, Lys 99) of lipopolysaccharide (LPS) binding protein on binding and transfer of LPS and subsequent immune cell activation. J. Immunol. 157:4648-4656.
14. Wright, S.D., R.A. Ramos, P.S. Tobias, R.J. Ulevitch, and J.C. Mathison. 1990. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 249:1431-1433.
15. Hailman, E., H.S. Lichenstein, M.M. Wurfel, D.S. Miller, D.A. Johnson, M. Kelley, L.B. Busse, M.M. Zukowski, and S.D. Wright. 1994. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J. Exp. Med. 179:269-277.
16. Tobias, P.S., K. Soldau, J.A. Gegner, D. Mintz, and R.J. Ulevitch. 1995. Lipopolysaccharide binding protein-mediated complexation of lipopolysaccharide with soluble CD14. J. Biol. Chem. 270:10482-10488.
17. Yu, B., and S.D. Wright. 1996. Catalytic properties of lipopolysaccharide (LPS) binding protein (LBP). Transfer of LPS to soluble CD14. J. Biol. Chem. 271:4100-4105.
18. Wurfel, M.M., S.T. Kunitake, H. Lichenstein, J.P. Kane, and S.D. Wright. 1994. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J. Exp. Med. 180:1025-1035.
19. Schumann, R.R., S.R. Leong, G.W. Flaggs, P.W. Gray, S.D. Wright, J.C. Mathison, P.S. Tobias, and R.J. Ulevitch. 1990. Structure and function of lipopolysaccharide binding protein. Science. 249:1429-1431.
20. Mathison, J.C., P.S. Tobias, E. Wolfson, and R.J. Ulevitch. 1992. Plasma lipopolysaccharide (LPS)-binding protein. A key component in macrophage recognition of gram-negative LPS. J. Immunol. 149:200-206.
21. Calvano, S.E., W.A. Thompson, M.N. Marra, S.M. Coyle, H.F. de Riesthal, R.K. Trousdale, P.S. Barie, R.W. Scott, L.L. Moldawer, and S.F. Lowry. 1994. Changes in polymorphonuclear leukocyte surface and plasma bactericidal/permeability-increasing protein and plasma lipopolysaccharide binding protein during endotoxemia or sepsis. Arch. Surg. 129:220-226.
22. Gallay, P., C. Barras, P.S. Tobias, T. Calandra, M.P. Glauser, and D. Heumann. 1994. Lipopolysaccharide (LPS)-binding protein in human serum determines the tumor necrosis factor response of monocytes to LPS. J. Infect. Dis. 170:1319-1322.
23. Froon, A.H., M.A. Dentener, J.W. Greve, G. Ramsay, and W.A. Buurman. 1995. Lipopolysaccharide toxicity-regulating proteins in bacteremia. J. Infect. Dis. 171:1250-1257.
24. Schumann, R.R., C.J. Kirschning, A. Unbehaun, H. Aherle, H.-P. Knopf, N. Lamping, R.J. Ulevitch, and F. Herrmann. 1996. The lipopolysaccharide-binding protein is a secretory class 1 acute-phase protein whose gene is transcriptionally activated by APRF/STAT-3 and other cytokine-inducible nuclear proteins. Mol. Cell. Biol. 16:3490-3503.
25. Opal, S.M., J.E. Palardy, M.N. Marra, C.J. Fisher, Jr., B.M. McKelligon, and R.W. Scott. 1994. Relative concentrations of endotoxin-binding proteins in body fluids during infection. Lancet. 344:429-431.
26. Schäfer, K., R.R. Schumann, S. Stöteknuel, J. Bohler, J. Schollmeyer, and G.J. Dobos. 1997. Lipopolysaccharide binding protein: a marker for intraperitoneal bacterial infection in patients with CAPD peritonitis. Adv. Perit. Dial. 13:210-213.
27. Gegner, J.A., R.J. Ulevitch, and P.S. Tobias. 1995. Lipopolysaccharide (LPS) signal transduction and clearance. Dual roles for LPS binding protein and membrane CD14. J. Biol. Chem. 270:5320-5325.
28. Grunwald, U., X.L. Fan, R.S. Jack, G. Workalemahu, A. Kallies, F. Stelter, and C. Schütt. 1996. Monocytes can phagocytose gram negative bacteria by a CD14 dependent mechanism. J. Immunol. 157:4119-4125.
29. Lengacher, S., C.V. Jongeneel, D. Le Roy, J.D. Lee, V. Kravchenko, R.J. Ulevitch, M.P. Glauser, and D. Heumann. 1996. Reactivity of murine and human recombinant LPS binding protein (LBP) with LPS and gram negative bacteria. J. Inflamm. 47:165-172.
30. Ulevitch, R.J., A.R. Johnston, and D.B. Weinstein. 1979. New function for high density lipoproteins: their participation in intravascular reactions of bacterial lipopolysaccharides (LPS). J. Clin. Invest. 64:1516-1524.
31. Levine, D.M., T.S. Parker, T.M. Donnelly, A. Walsh, and A.L. Rubin. 1993. In vivo protection against endotoxin by plasma high density lipoprotein. Proc. Natl. Acad. Sci. USA. 90:12040-12044.
32. Pajkrt, D., J.E. Doran, F. Koster, P.G. Lerch, B. Arnet, T. van der Poll, J.W. ten Cate, and S.J.H. van Deventer. 1996. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J. Exp. Med. 185:1601-1608.
33. Jack, R.S., X. Fan, M. Bernheiden, G. Rune, M. Ehlers, A. Weber, G. Kirsch, R. Mentel, B. Fürll, M. Freudenberg, et al. 1997. Lipopolysaccharide-binding protein is required to combat a murine Gram-negative bacterial infection. Nature. 389:742-745.
34. Wurfel, M.M., B.G. Monks, R.R. Ingalls, R.L. Dedrick, R. Delude, D. Zhou, N. Lamping, R.R. Schumann, R. Thieringer, M.J. Fenton, et al. 1997. Targeted deletion of the LBP gene leads to profound suppression of LPS responses ex vivo while in vivo responses remain intact. J. Exp. Med. 186:2051-2056.
35. Lottenberg, R., U. Christensen, C.M. Jackson, and P.L. Coleman. 1981. Assay of coagulation proteases using peptide chromogenic and fluorogenic substrates. Methods Enzymol. 80:342-361.
36. Szabó, C., G.J. Southan, and C. Thiemermann. 1994. Beneficial effects and improved survival rodent models of septic shock with S-methylisothiourea sulfate, a potent and selective inhibitor of inducible nitric oxide synthase. Proc. Natl. Acad. Sci. USA. 91:12472-12476.
37. Beutler, B., J. Mahoney, T.N. Le, P. Pekala, and A. Cerami. 1985. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J. Exp. Med. 161:984-995.
38. Galanos, C., M.A. Freudenberg, and W. Reutter. 1979. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc. Natl. Acad. Sci. USA. 76:5939-5943.
39. Lehmann, V., M.A. Freudenberg, and C. Galanos. 1987. Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice. J. Exp. Med. 165:657-663.
40. Gallay, P., D. Heumann, D. Le Roy, C. Barras, and M.P. Glauser. 1993. Lipopolysaccharide-binding protein as a major plasma protein responsible for endotoxemic shock. Proc. Natl. Acad. Sci. USA. 90:9935-9938.
41. Gallay, P., D. Heumann, D. Le Roy, C. Barras, and M.P. Glauser. 1994. Mode of action of anti-lipopolysaccharide binding protein antibodies for prevention of endotoxemic shock in mice. Proc. Natl. Acad. Sci. USA. 91:7922-7926.
42. Hailman, E., T. Vasselon, M. Kelley, L.A. Busse, M.C. Hu, H.S. Lichenstein, P.A. Detmers, and S.D. Wright. 1996. Stimulation of macrophages and neutrophils by complexes of lipopolysaccharide and soluble CD14. J. Immunol. 156:4384-4390.
43. Haziot, A., E. Ferrero, F. Kontgen, N. Hijiya, S. Yamamoto, J. Silver, C.L. Stewart, and S.M. Goyert. 1996. Resistance to endotoxin shock and reduced dissemination of gram negative bacteria in CD14 deficient mice. Immunity. 4:407-414.
44. Ferrero, E., D. Jiao, B.Z. Tsuberi, L. Tesio, G.W. Rong, A. Haziot, and S.M. Goyert. 1993. Transgenic mice expressing human CD14 are hypersensitive to lipopolysaccharide. Proc. Natl. Acad. Sci. USA. 90:2380-2384.
45. Haziot, A., G.W. Rong, X.Y. Lin, J. Silver, and S.M. Goyert. 1995. Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J. Immunol. 154:6529-6532.
46. Abrahamson, S.L., H.M. Wu, R.E. Williams, K. Der, N. Ottah, R. Little, H. Gazzano-Santoro, G. Theofan, R. Bauer, S. Leigh, et al. 1997. Biochemical characterization of recombinant fusions of lipopolysaccharide binding protein and bactericidal/permeability increasing protein: implications in biological activity. J. Biol. Chem. 272:2149-2155.
47. Amura, C.R., L.-C. Chen, N. Hirohashi, M.-G. Lei, and D.C. Morrison. 1997. Two functionally independent pathways for lipopolysaccharide-dependent activation of mouse peritoneal macrophages. J. Immunol. 159:5079-5083.
48. Troelstra A., B.N. Giepmans, K.P. van Kessel, H.S. Lichenstein, J. Verhoef, and J.A. van Strijp. 1997. Dual effects of soluble CD14 on LPS priming of neutrophils. J. Leukocyte Biol. 61:173-178.
49. Tobias, P.S., K. Soldau, N.M. Iovine, P. Elsbach, and J. Weiss. 1997. Lipopolysaccharide (LPS) binding proteins BPI and LBP form different types of complexes with LPS. J. Biol. Chem. 272:18682-18685.
50. Massamiri, T., P.S. Tobias, and L.K. Curtiss. 1997. Structural determinants for the interaction of lipopolysaccharide binding protein with purified high density lipoproteins: role ol apolipoprotein A-I. J. Lipid. Res. 38:516-525.
51. Carroll, S.F., R.L. Dedrick, and M.L. White. 1997. Plasma levels of lipopolysaccharide binding protein (LBP) correlate with outcome in sepsis and other patients. Shock. 8:101. (Abstr.)